Document is current

Any future updates will be listed below

Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1038/s41598-026-42768-6

Published Online: 2026-04-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark